$IKNA News
Last published 1y ago
- 1y agoIKNAInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 MillionGlobeNewswireThe combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive
- 1y agoIKNAPSTXIkena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged CompanyGlobeNewswireBOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief
- 1y agoIKNAIkena Oncology Announces Stockholder Approval of Merger with Inmagene BiopharmaceuticalsGlobeNewswireCombined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA)
- 1y agoIKNAIkena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene BiopharmaceuticalsGlobeNewswireBOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " the "Company")) today announced that Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass Lewis")
- 1y agoIKNAIOVATRAWTraws Pharma Announces Management UpdatesGlobeNewswireWerner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc.
- 1y agoIKNAIkena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private PlacementGlobeNewswireInmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is
- 2y agoIKNAIkena Oncology Reports Third Quarter 2024 Financial ResultsGlobeNewswireBOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")) today announced financial results for the third quarter ended September 30, 2024, and provided an update regarding its
- 2y agoIKNAIkena Oncology Reports Second Quarter 2024 Financial ResultsGlobeNewswireBOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its
- 2y agoIKNAUPDATE – Ikena Oncology Announces Strategic UpdateGlobeNewswireIkena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic
- 2y agoIKNAIkena Oncology Announces Strategic UpdateGlobeNewswireIkena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic
- 2y agoIKNAIkena Oncology Reports First Quarter 2024 Financial Results and Corporate UpdateGlobeNewswireStrong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant
- 2y agoIKNAIkena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology ForumGlobeNewswireBOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that
- 2y agoIKNAIkena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireIK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and
- 2y agoIKNAIkena Oncology to Participate in TD Cowen 44th Annual Health Care ConferenceGlobeNewswireBOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that
- 2y agoIKNAIkena Oncology Appoints Caroline Germa, M.D. as Chief Medical OfficerGlobeNewswireCaroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy and oversee the
- 2y agoIKNAIkena Oncology Outlines Key Priorities and Provides Corporate UpdatesGlobeNewswireIK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology
- 3y agoIKNAIkena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial ResultsGlobeNewswireFavorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions Encouraging
- 3y agoIKNAIkena Oncology to Present at Multiple November 2023 Investor ConferencesGlobeNewswireBOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that
- 3y agoIKNAIkena Oncology to Participate in September 2023 Investor ConferencesGlobeNewswireBOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that
- 3y agoIKNAIkena Oncology Reports Second Quarter 2023 Financial Results and Corporate UpdateGlobeNewswireInitial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by year end 2023
- 3y agoIKNAIkena Oncology Acquires Pionyr Immunotherapeutics in All-Stock TransactionGlobeNewswireIkena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023
- 3y agoIKNAIkena Oncology to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will
- 3y agoIKNAIkena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology PipelineGlobeNewswireLead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date Preclinical data at AACR Annual Meeting demonstrated IK-930 TEAD1
- 3y agoIKNAIkena Oncology Announces $40 Million Underwritten OfferingGlobeNewswireBOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena", "Company")), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of
- 3y agoIKNAIkena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology DaysGlobeNewswireBOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will
- 3y agoIKNAIkena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual MeetingGlobeNewswireIK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930's differentiated paralog selectivity and robust repressor activity in complex with VGLL4 are
- 3y agoIKNAIkena Oncology Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswireFocused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation cohorts, Fast Track and
- 3y agoIKNAIkena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS TargetingGlobeNewswireBOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the Company is
- 3y agoIKNAIkena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial CarcinomaGlobeNewswireBOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and
- 3y agoIKNAIkena Oncology to Participate in Cowen 43rd Annual Health Care ConferenceGlobeNewswireBOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will
- 3y agoIKNAIkena Oncology Appoints Owen Hughes as Board ChairGlobeNewswireOwen Hughes joins Ikena Board as independent director with operational and public company experience Ron Renaud steps down as he transitions into investment management role BOSTON, Dec. 19, 2022
- 3y agoIKNAIkena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate UpdateGlobeNewswireNovel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 Company prioritizes
- 3y agoIKNAIkena Oncology to Participate in the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewswireBOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will
- 4y agoIKNAIkena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial CarcinomaGlobeNewswireIK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial response with DoR of 14.9
- 4y agoIKNAIkena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswireInitial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab Progressing lead targeted oncology
- 4y agoIKNAIkena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic ResistanceGlobeNewswireBOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a poster presentation
- 4y agoAZNIKNAIkena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo PathwayGlobeNewswireClinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers Company shares further detail on the differentiators of IK-930, a
- 4y agoIKNAIkena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingGlobeNewswireBOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl Hydrocar
- 4y agoIKNAIkena Oncology to Participate in September 2022 Investor ConferencesGlobeNewswireBOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor
- 4y agoIKNAIkena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswireBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the second quarter ended June 30, 202
- 4y agoIKNAIkena Oncology to Participate in the William Blair Biotech Focus Conference 2022GlobeNewswireBOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that Mark Manfredi, Ph.D., Chief Executive Officer of Ikena
- 4y agoIKNAIkena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient MesotheliomaGlobeNewswireBOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has grante
- 4y agoIKNAIkena Oncology to Participate in Spring 2022 Investor ConferencesGlobeNewswireBOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will be presenting at the H.C. Wainwright Gl
- 4y agoIKNAIkena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswireIK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary anti-tumor activity First patients dosed in our first-in-human clinical trial of IK-930 targeting TE
- 4y agoIKNASeismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business OfficerBusiness WireSeismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier brings over 16 years of company building experie
- 4y agoIKNAIkena Oncology and Vall d'Hebron Institute of Oncology Announce Research & Development CollaborationGlobeNewswireBOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, and the Vall d'Hebron Institute of Oncology (VHIO) today announced an alliance to enab
- 4y agoIKNAIkena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual MeetingGlobeNewswireBOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters a
- 4y agoIKNAIkena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate DevelopmentGlobeNewswireBOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the appointment of Jotin Marango, M.D., Ph.D., to Chief Fi
- 4y agoIKNAIkena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate UpdateGlobeNewswireOver $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead targeted oncology program, into the clinic, continuing leadership in the Hippo pathway therapeutic landscape Expanded IK-175
- 4y agoIKNAIkena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireBOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will participate in an oral presentation highlighting the